Sezary Syndrome Clinical Trial
Official title:
A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas
This phase I trial studies the side effects and best dose of lenalidomide when given together with brentuximab vedotin in treating patients with T-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphomas.
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD)/Recommended Phase 2 dose (RP2D) of brentuximab
vedotin in combination with lenalidomide in patients with relapsed/ refractory cutaneous
T-cell lymphoma (CTCL).
II. Assess safety and tolerability of brentuximab vedotin in combination with lenalidomide in
patients with relapsed/ refractory CTCL.
SECONDARY OBJECTIVES:
I. Estimate the rate of objective global response that lasts at least 4 months (ORR4) ,
complete response (CR) rate, progression-free survival (PFS) of brentuximab vedotin in
combination with lenalidomide in patients with relapsed/ refractory CTCL.
II. Estimate the rate and duration of clinically meaningful reduction in pruritus (CMRP).
III. Correlate response to baseline CD30 levels in tissue samples.
TERTIARY OBJECTIVES:
I. Estimate the response endpoints incorporating Lugano response criteria for patients with
PET+ disease.
II. Explore temporal gene expression profile in skin/ blood samples that may predict response
to combination therapy.
OUTLINE: This is a dose-escalation study of lenalidomide.
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1 and
lenalidomide orally (PO) once daily (QD) on days 1-14. Treatment repeats every 21 days for up
to 17 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then up to 12
months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02978625 -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
|
Phase 2 | |
| Completed |
NCT00099593 -
Immunization Against Tumor Cells in Sezary Syndrome
|
Phase 2 | |
| Completed |
NCT00051012 -
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
|
Phase 4 | |
| Active, not recruiting |
NCT04312841 -
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
|
Phase 2 | |
| Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
| Recruiting |
NCT00177268 -
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
|
||
| Recruiting |
NCT04930653 -
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT04955340 -
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
|
Phase 1 | |
| Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04960618 -
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT02953301 -
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
|
Phase 2 | |
| Completed |
NCT00254332 -
Effect of Denileukin Diftitox on Immune System in CTCL Patients
|
N/A | |
| Completed |
NCT00896493 -
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05879458 -
Ritlecitinib in CTCL
|
Phase 2 | |
| Recruiting |
NCT03011814 -
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04256018 -
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
|
Phase 2 | |
| Completed |
NCT01134341 -
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT00748319 -
Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma
|
N/A | |
| Completed |
NCT03905135 -
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT01396070 -
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
|
N/A |